-
Severe Persistent Asthma
- Adjunct only
- Other Leukotriene Modifiers are preferred
- Approved only in age >=12 years and only as adjunct in Severe Asthma
- Dose: 1200 mg orally two times daily
- Attenuates bronchoconstriction and inflammation
-
Leukotriene Synthesis Inhibitor (inhibits 5-lipoxygenase)
- Contrast with Leukotriene Receptor Antagonists (Zafirlukast or Accolate, Montelukast or Singulair)
- See Leukotriene Receptor Antagonist
- More adverse effects than other Leukotriene Modifiers (e.g. Montelukast, Zafirlukast)
- Dyspepsia
- Nausea
- Hepatotoxicity (5% of patients)
- Monitor liver enzymes every 3 months
- See See Leukotriene Receptor Antagonist
- Pregnancy Category C
- Unknown safety in Lactation
- Zileuton increases other drug levels, potentiating their action
- (2020) Drugs for Asthma, Med Lett Drug Ther 62: 193-200
- (1996) Med Lett Drugs Ther 38:111-2 [PubMed]
- (2000) Med Lett Drugs Ther 42:22-3 [PubMed]
- Scow (2007) Am Fam Physician 75:65-70 [PubMed]
- Wilson (2001) Chest 119:2021-6 [PubMed]